TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma
0301 basic medicine
Osteosarcoma
Osteoblasts
Reverse Transcriptase Polymerase Chain Reaction
Blotting, Western
RNA-Binding Proteins
Apoptosis
Bone Neoplasms
Real-Time Polymerase Chain Reaction
3. Good health
Gene Expression Regulation, Neoplastic
Transforming Growth Factor beta1
MicroRNAs
03 medical and health sciences
Drug Resistance, Neoplasm
Tumor Cells, Cultured
Humans
RNA, Messenger
RNA, Small Interfering
Apoptosis Regulatory Proteins
Cell Proliferation
Signal Transduction
DOI:
10.1007/s00432-015-2028-9
Publication Date:
2015-08-14T09:14:30Z
AUTHORS (7)
ABSTRACT
A number of studies have demonstrated that microRNAs play a critical role in osteosarcoma progression, therapy and drug resistance. MicroRNA-202 has proven to be dysregulated in many human cancer studies. This study aimed to explore miR-202 contributions to drug resistance in osteosarcoma.miR-202 expression was measured by real-time PCR in patient tissues, cell lines or cells treated with TGF-β1, using siRNA to knock down the expression of Smad2, Smad3 and Smad4. miR-202 mimics, inhibitor and scramble siRNA were transfected into osteosarcoma cells to observe effects on cell apoptosis and drug resistance. Moreover, relationships of miR-202 level with PDCD4 were investigated by luciferase reporter assay, real-time PCR and Western blotting.We found that miR-202 is overexpressed in osteosarcoma tissues when compared with normal human osteoblasts and TGF-β1 can induce the expression of miR-202. Transfection of miR-202 mimics into osteosarcoma cell lines significantly promotes chemotherapy resistance by targeting PDCD4, a tumor suppressor which is involved in apoptosis. In contrast, transfection of miR-202 inhibitor enhances the drug sensitivity and apoptosis.This study provides new insights into miRNA-202 in osteosarcoma as a potential molecular target for chemotherapy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (32)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....